Dapagliflozin Enhances Gut Barrier Function in Rats with Chronic Myocardial Infarction by Modulating Gut Microbiota Balance

This study investigates the gut microbiota composition in a rat model of chronic myocardial infarction (CMI) and explores the potential impact of dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor. Male Wistar rats were subjected to left anterior descending (LAD) coronary artery ligation to induce CMI or underwent sham surgery. After one week, rats with confirmed myocardial dysfunction were randomized to receive either vehicle or dapagliflozin (1 mg/kg/day, orally) for ten weeks. Fecal samples were collected for 16S rRNA gene sequencing to assess microbial composition and diversity. This dataset supports research on the interaction between cardiac disease and gut microbiota, as well as the microbiome-modulating potential of SGLT2 inhibitors.

本研究针对慢性心肌梗死（CMI）大鼠模型的肠道菌群组成展开探究，并分析达格列净——一种钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂——的潜在影响。将雄性Wistar大鼠通过左前降支（LAD）冠状动脉结扎术构建CMI模型，其余大鼠接受假手术。造模一周后，经确认存在心肌功能障碍的大鼠被随机分为两组，分别给予赋形剂或达格列净（1 mg/kg/天，口服），持续给药十周。收集粪便样本进行16S rRNA基因测序，以评估菌群组成与多样性。本数据集可为心脏疾病与肠道菌群的相互作用研究，以及SGLT2抑制剂的菌群调控潜力相关研究提供支持。